Empagliflozin improves diastolic function in obese ZSF1 rats by restoring the cardiac mitochondrial respiratory capacity.

27 August 2023 (10:15 - 10:45)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Antje Schauer

Heart Centre Dresden - Dresden Technical University Hospital, Dresden (Germany)

3 More presentations in this session

Presentation thumbnail

The SGLT2I Dapagliflozin reverses metabolic stress driving myocardial inflammation in a mouse model of heart failure with preserved ejection fraction: insights from single-cell RNA sequencing

Doctor C. Panico (Milan, IT)

Abstract Slides Video

Presentation thumbnail

Diabetes and chronic kidney disease synergistically contribute to left ventricular diastolic dysfunction and coronary microvascular disease in swine

Mr J. Hamers (Munich, DE)

Abstract Slides Video

Presentation thumbnail

Epicardial tissue derived leptin promotes myocardial injury in metabolic syndrome rats through PKC/NADPH oxidase/ROS pathway

Doctor H. Chen (Zhengzhou, CN)

Abstract Slides

Access the full session

Session thumbnail

Heart failure with preserved ejection fraction: bench

The Event

Event poster

ESC Congress 2023

27 August 2023 10:15 CET

You may be interested in

Congress Presentation

Beneficial effects of treatment with a soluble guanylate cyclase stimulator on cardiac function and mitochondrial activity in an animal model of early-stage HFpEF

Congress Presentation

Empagliflozin reduces extracellular volume and myocardial sodium content in patients with heart failure and preserved ejection fraction and correlates with reverse cardiac remodeling (EMPAG CMR-HF)

Congress Presentation

Effects of empagliflozin on cardio-renal interaction in heart failure with reduced ejection fraction: results from in-vivo experiments and the CINNAMON-study

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources